Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out which doses of talimogene laherparepvec (T-Vec) can
be given safely to participants with pancreatic cancer that is either too big to be taken out
by surgery or has spread to other parts of the body. The study will also see if T-Vec can
cause tumor shrinkage or prevent its growth.
The primary objective is to determine the rate of dose limiting toxicity at tested doses of
talimogene laherparepvec administered endoscopically to pancreatic tumors, and to identify a
maximum tolerated dose (MTD).
Secondary exploratory efficacy endpoints include change in longest diameter in the injected
lesion(s), overall response rate (ORR) per RECIST v1.1 and modified immune-related response
criteria (mirRC as defined in section 11), progression free survival (PFS) and overall
survival (OS) at 6, 12, and 24 months.
Funding Source - FDA OOPD